Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, ON2 Herestraat 49, Box 521, 3000, Leuven, Belgium.
Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), KU Leuven, Leuven, Belgium.
Clin Pharmacokinet. 2024 Oct;63(10):1407-1421. doi: 10.1007/s40262-024-01414-y. Epub 2024 Sep 20.
Tacrolimus is an immunosuppressant commonly administered after solid organ transplantation. It is characterized by a narrow therapeutic window and high variability in exposure, demanding personalized dosing. In recent years, population pharmacokinetic models have been suggested to guide model-informed precision dosing of tacrolimus. We aimed to provide a comprehensive overview of population pharmacokinetic models and model-informed precision dosing software modules of tacrolimus in all solid organ transplant settings, including a simulation-based investigation of the impact of covariates on exposure and target attainment.
We performed a systematic literature search to identify population pharmacokinetic models of tacrolimus in solid organ transplant recipients. We integrated selected population pharmacokinetic models into an interactive software tool that allows dosing simulations, Bayesian forecasting, and investigation of the impact of covariates on exposure and target attainment. We conducted a web survey amongst model-informed precision dosing software tool providers and benchmarked publicly available tools in terms of models, target populations, and clinical integration.
We identified 80 population pharmacokinetic models, including 44 one-compartment and 36 two-compartment models. The most frequently retained covariates on clearance and distribution parameters were cytochrome P450 3A5 polymorphisms and body weight, respectively. Our simulation tool, hosted at https://lpmx.shinyapps.io/tacrolimus/ , allows thorough investigation of the impact of covariates on exposure and target attainment. We identified 15 model-informed precision dosing software tool providers, of which ten offer a tacrolimus solution and nine completed the survey.
Our work provides a comprehensive overview of the landscape of available tacrolimus population pharmacokinetic models and model-informed precision dosing software modules. Our simulation tool allows an interactive thorough exploration of covariates on exposure and target attainment.
他克莫司是一种常用于实体器官移植后的免疫抑制剂。它的治疗窗狭窄,暴露量变异性高,需要个体化给药。近年来,群体药代动力学模型被建议用于指导他克莫司的模型指导下精准给药。我们旨在全面概述所有实体器官移植背景下的他克莫司群体药代动力学模型和模型指导下的精准给药软件模块,并基于模拟研究协变量对暴露量和目标达成的影响。
我们进行了系统文献检索,以确定实体器官移植受者中他克莫司的群体药代动力学模型。我们将选定的群体药代动力学模型整合到一个交互式软件工具中,该工具允许进行给药模拟、贝叶斯预测,并研究协变量对暴露量和目标达成的影响。我们对模型指导下的精准给药软件工具供应商进行了网络调查,并根据模型、目标人群和临床整合情况对公开可用的工具进行了基准测试。
我们确定了 80 个群体药代动力学模型,包括 44 个单室模型和 36 个双室模型。清除率和分布参数最常保留的协变量分别是细胞色素 P450 3A5 多态性和体重。我们的模拟工具位于 https://lpmx.shinyapps.io/tacrolimus/ ,可以深入研究协变量对暴露量和目标达成的影响。我们确定了 15 个模型指导下的精准给药软件工具供应商,其中 10 个提供他克莫司解决方案,9 个完成了调查。
我们的工作全面概述了现有的他克莫司群体药代动力学模型和模型指导下的精准给药软件模块的情况。我们的模拟工具允许对暴露量和目标达成的协变量进行交互式深入探索。